DMA if you are correct in your assumptions with where the scenario is between BTA and GSK.
Logically it could explain the total lack of promotion of Relenza, in a situation where it should be in front of everyone's faces, especially now with Bali's cases of H5N1.
Yet all we are seeing on TV news is vaccination's against flu...and in the background a packet of tamiflu.
Conversely, I assumed with the litigation that GSK were utilising the lack of advertising of Relenza to promote their side of the story, once it hit trial.
The other issue that is worrying, is the continuing slide in the SP, with BTA being in a reasonably sound cash flow position and with other positive products almost ready for the market place.
Does it not leave the Company vulnerable for an easy takeover target ?
biotas open briefing, page-12
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)